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Growing evidence suggests that Alzheimer’s disease and other types of dementia are underdiagnosed and poorly documented.
In our study, we describe patterns of dementia coding and treatment in the Veteran’s Administration New England Healthcare
System. We conducted a retrospective cohort study with new outpatient ICD-9 codes for several types of dementia between 2002
and 2009. We examined healthcare utilization, medication use, initial dementia diagnoses, and changes in diagnoses over time by
provider type. 8,999 veterans received new dementia diagnoses during the study period. Only 18.3% received a code for cognitive
impairment other than dementia, most often “memory loss” (65.2%) prior to dementia diagnosis. Two-thirds of patients received
theirinitialcodefromaPCP.TheetiologyofdementiawasoftenneverspecifiedbyICD-9code,evenbyspecialists.Patientsfollowed
up exclusively by PCPs had lower rates of neuroimaging and were less likely to receive dementia medication. Emergency room
visits and hospitalizations were frequent in all patients but highest in those seen by dementia specialists. Dementia medications
are commonly used off-label. Our results suggest that, for the majority the patients, no prodrome of the dementia syndrome is
documented with diagnostic code, and patients who do not see dementia specialists have less extensive diagnostic assessment and
treatment.
1. Introduction
Approximately 13% of Americans over age 65 have Alzheim-
er’s disease (AD), the most common cause of dementia [1].
This prevalence estimate comes from carefully conducted
population-based studies and is substantially higher than
that seen in healthcare settings. The prevalence of all types
of dementia among users of the U.S. Department of Vet-
erans Affairs Healthcare System (VAHCS) aged 55 years
and older, as defined by ICD9 diagnosis codes, is 7.3%
[2]. Growing evidence suggests that AD and other types of
dementia are under-diagnosed and poorly documented in
most primary care settings, particularly in their early stages
[3, 4].
While cognitive screening in asymptomatic individuals
is not widely recommended [5], there is a growing appre-
ciation of the importance of early recognition of dementia.
Patients with unrecognized impairment do not get tested for
reversiblecausesofdementia,donotgetcounselingregarding
the disease process or advanced care planning, and are
not offered treatment. Undiagnosed cognitive impairment
can compromise patient safety, medication compliance, and
patient-doctor communication [3, 6].
Integrated Service Network 1 (VISN1), the New England
region of VAHCS, serves over 230,000 patients. To better
understandpatternsofdementiacodingandtreatmentinthis
population, we assembled a retrospective cohort of VISN1
patients with the three most common dementia diagnoses.
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Our goals were to describe patterns of diagnostic coding and
treatmentbyprovidertypeandhealthcareutilizationpatterns
around the diagnostic period.
2. Methods
Data for this study were extracted from the VA National
Patient Care and Decision Support Systems Databases and
the clinical, laboratory, and pharmacy files of VISN1 data
system. This study was reviewed and approved by the
Institutional Review Board and Research and Development
Committees of the VA Boston Healthcare System.
All subjects in VISN1 with healthcare service between
January 1, 2002, and December 31, 2009, who received an
outpatient ICD-9 code for dementia of the Alzheimer’s type
(331.0, 290.0–290.3; DAT), vascular dementia (290.4–290.43;
VD), or dementia not otherwise specified (294.8; DNOS)
from a PCP, neurologist, geriatrician, psychiatrist, psycholo-
gist, or neuropsychologist were eligible for study inclusion.
Cognitive impairment was defined as any of the following
codes:(1)mildcognitiveimpairment(MCI,331.83),(2)mem-
ory loss (780.93), (3) late cognitive effects of cerebrovascular
disease (438.0, CDCVD), and (4) cognitive disorder not
otherwise specified (CDNOS, 294.9). All patients had to be
at least 55 years old at the time of first dementia diagnosis.
A one-year baseline period prior to first dementia diagnosis
was used to evaluate prior history of resource utilization and
medication use. ICD-9 codes for cognitive impairment were
allowed during the 12 months prior to a recorded dementia
diagnosis. Individuals were followed for one year after the
date of first dementia diagnosis, unless this was preceded
by either their last visit to the VA Healthcare System, death,
or the calendar end of the study (December 31, 2009). The
one-year period before and after first dementia diagnosis is
referred to as the “peridiagnostic period.”
We defined the initial diagnosis as the first code for
cognitive impairment. We identified all occurrences of diag-
noses for dementia or cognitive impairment during the study
period. We defined the final diagnosis as follows: (1) patients
wereconsideredtohaveafinaldiagnosisofDA TorVDifthey
had at least one relevant code and no codes for other specific
types of dementia (DNOS was permitted); (2) patients with
codesforbothADandVDintheabsenceofanyotherspecific
dementia code were considered to have a final diagnosis of
mixed dementia; (3) patients with one or more codes for
DNOS and no specific codes for dementia or Parkinson’s
disease were classified as DNOS. We identified the type of
provider to give the initial cognitive diagnosis (PCP, mental
healthprovider,neuropsychologist, geriatrician,neurologist,
and other providers). We also identified the type of provider
patients seen in the year before and after diagnosis and
created the following categories: (1) followed by PCPs only;
(2) ever seen by neurologists or geriatricians; (3) ever seen by
mental health providers (psychiatrists or psychologists).
2.1. Statistical Analyses. We report summary statistics (fre-
quenciesandproportionsforcategoricalvariablesandmeans
for continuous data) to describe diagnostic patterns by
provider type, baseline characteristics of dementia patients,
a n dr e s o u r c eu t i l i z a t i o n .W ee x a m i n e dt h efi r s ta n dfi n a l
dementia diagnoses by provider type. We described overall
resourceutilizationratesintheperi-diagnosticperiod(1year
before and after diagnosis). Resource utilization included
visits to the emergency room (ER) and hospitalizations and
use of neuroimaging and medications (dementia medica-
tions, antipsychotics, and antidepressants). Comorbidities
were defined by outpatient ICD-9 codes and imaging studies
by CPT codes. We used the VISN1 pharmacy file to describe
the use of dementia medications (cholinesterase inhibitors
and memantine), antipsychotics, and antidepressants. All
statistical analyses were performed using SAS (Statistical
Analysis Software) 9.2.
3. Results
We identified 8,999 subjects who met study inclusion criteria
(Table 1). Only 1,643 (18.3%) patients received a diagnosis
for a prodromal cognitive syndrome prior to their initial
dementia code. Among patients with cognitive impairment,
memory loss was the term most frequently assigned (65.2%),
followed by CDNOS (29.7%). MCI (2.7%) was rarely used
as an initial diagnosis. Among patients initially diagnosed
with dementia, DNOS (41.9%) was the most common initial
dementia diagnosis, followed by DAT (25.0%) and VD
(14.9%).Duringtheperi-diagnosticperiod,26.9%ofpatients
were seen by neurologists or geriatricians, 34.1% by mental
healthspecialists,and39.1%byPCPsonly.PCPsdocumented
the initial dementia code for 66.5% of patients (𝑛 = 5,998),
followed by specialists without expertise in dementia (9.3%),
mental health providers (8.2%), and neurologists (7.7%). The
most frequent initial dementia diagnosis given by neurolo-
gists was DAT; for all other provider types DNOS was most
frequently used. The mean age at first dementia code of this
predominantly male cohort was 79.5 years. Patients followed
exclusively by PCPs had the oldest mean age (80.2yrs), while
t h o s es e e nb yp s y c h i a t r i s t sa n dp s y c h o l o g i s t sw e r ey o u n g e r
(76.5yrs) and had more comorbidity than other groups.
The most common final dementia diagnosis was DNOS
(44.3%), followed by DAT (31.9%), VD (18.9%), and mixed
DAT/vascular (4.8%). The distribution of final diagnoses by
physician type is displayed in Figure 1. The initial dementia
diagnosis was changed in less than 30% of patients who
were followed by PCPs only, while among those seen by
neurologists and geriatricians 40.8% of initial AD diagnoses,
79% of initial VD diagnoses, and 64.4% of initial DNOS
diagnoses were changed.
Figure 2 summarizes healthcare utilization in the peri-
diagnostic period. Rates of ER visits and hospitalization were
highest in patients seen by psychiatrists and psychologists
(26.3%) or neurologists and geriatricians (24.0%) and were
lowerinthoseseenbyPCPsonly(16.9%).Imagingrateswere
much higher among patients seen by neurologists and geri-
atricians (52.2%) than by other dementia specialists (23.1%)
and PCPs (14.3%). Dementia medications were prescribed
in 66.8% of patients with a final diagnosis of DAT, 27.7% of
patientswithVDonly,and65.7%ofpatientswithDNOSonly.International Journal of Alzheimer’s Disease 3
Table 1: Initial dementia diagnoses by provider type.
Diagnosis by
Dementia, 𝑁=7 ,356 Cognitive impairment, 𝑁=1 ,643
Total AD VD DNOS MCI
∗ Memory loss CD-CVD CDNOS
𝑁 (%) 𝑁 (%) 𝑁 (%) 𝑁 (%) 𝑁 (%) 𝑁 (%) 𝑁 (%)
PCP 1519 (67.6) 1083 (80.8) 2409 (63.9) 17 (37.8) 763 (71.2) 11 (28.2) 186 (38.1) 5988 (66.5)
Mental health (psychology/psychiatry) 147 (6.5) 67 (5.0) 410 (10.9) 9 (20.0) 28 (2.6) 2 (5.1) 75 (15.4) 738 (8.2)
Neuropsychology 35 (1.6) 31 (2.3) 325 (8.6) 1 (2.2) 8 (0.7) 1 (2.6) 49 (10.0) 450 (5.0)
Geriatrician 90 (5.9) 33 (2.5) 99 (2.6) 3 (6.6) 35 (3.2) 9 (23.1) 31 (6.4) 300 (3.3)
Neurologist 245 (10.0) 40 (3.0) 166 (4.4) 7 (15.6) 150 (14.2) 10 (25.6) 71 (14.5) 689 (7.7)
Other providers 211 (8.4) 86 (6.4) 360 (9.6) 8 (17.8) 87 (8.1) 6 (15.4) 76 (15.6) 834 (9.3)
Total 2247 (100) 1340 (100) 3769 (100) 45 (100) 1071 (100) 39 (100) 488 (100) 8999 (100)
DAT: Alzheimer’s type dementia; VD: vascular dementia; DNOS:dementia not otherwise specified; MCI: mild cognitive impairment; CD-CVD:late cognitive
effects of cerebrovascular disease; CDNOS: cognitive disorder not otherwise specified.
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Figure 1: Distribution of final dementia diagnoses by provider
category.
The rate of dementia medication use was 86.9% in those seen
by neurologists or geriatricians, 62.6% in those followed up
only by PCPs, and 56.1% in those seen by the other dementia
specialists.
4. Discussion
Dementia is a chronic, slowly progressive condition whose
diagnosis is frequently missed by patients, family members
and medical providers. In this retrospective cohort study
among veterans diagnosed with dementia in the VA New
England Healthcare System, we found that few patients are
given a diagnosis of cognitive impairment prior to their first
dementia diagnosis. This is despite the fact that many of
them have been followed up in the system for years. The
majority of patients receive their first dementia diagnosis
from a PCP. Compared to patients who see a geriatrician
or neurologist, dementia patients followed up exclusively by
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Figure 2: Resource utilization during peridiagnostic period by
provider type one year before and after first dementia diagnosis.
PCPs are less likely to receive a specific dementia diagnosis
a n dl e s sl i k e l yt oh a v et h e i ri n i t i a ld i a g n o s i sc h a n g eo v e r
time.Theyarealsolesslikelytoha veneuroimagingorreceive
dementia medication. The rates of emergency room care and
hospitalization were substantial in the year before and after
initial dementia diagnosis. Together, these findings suggest
that, for the majority of VA patients, dementia is likely not
diagnosed at an early stage, and patients who do not see
dementiaspecialistshavelessextensivediagnosticassessment
and treatment.
L e s st h a n2 0 %o ft h ep a t i e n t si no u rc o h o r th a dac o d e
for cognitive impairment prior to dementia. Underreporting
of cognitive impairment in primary care is an important
cause of delay in the diagnosis of DAT, a dementia for which
there is approved treatment that may benefit even those
with early dementia [7, 8]. Accurate diagnosis of dementia,
especially by PCPs, is an ongoing challenge. A European4 International Journal of Alzheimer’s Disease
study of dementia diagnosis in primary care found that
clinicians identified dementia by clinical judgment 73% of
the time but only documented the diagnosis for 38% of their
patients [9]. Severity of cognitive impairment seems to be
a major predictor of documentation. According to a recent
meta-analysis of 8 studies in a non-VA setting, diagnostic
sensitivity for dementia by PCPs was only 49% [10]. Over
60% of patients with severe dementia were diagnosed, as
compared to 9–41% of those with early dementia. Overall,
the findings of this study suggest that about half of the types
of dementia go undiagnosed in the primary care setting.
Benefits of an earlier diagnosis include the opportunity
for education, management of neuropsychiatric symptoms,
avoidance of medications that worsen cognitive function,
improved medication safety and compliance, and help with
support services and future planning.
Thisstudyhighlightstheoveruseofnonspecificdementia
diagnosesbyVISN1providersbutreflectsamuchwidertrend
both within and outside the VA [2, 11]. PCPs infrequently
changed the initial dementia diagnosis over time, while
geriatriciansandneurologistsfrequentlychangedDNOStoa
specificdiagnosis.Neuropsychologistswerethemostlikelyof
all providers to use a nonspecific diagnosis, perhaps because
they defer making a definitive diagnosis to the provider
who ordered the testing. Neurologists and geriatricians were
substantially more likely to obtain neuroimaging than PCPs.
Neurologists were the most likely to provide patients with a
specific dementia diagnosis. It is possible that more compli-
cated patients are referred to specialists, but this would not
a c c o u n tf o rt h eh i g hp r e v a l e n c eo fn o n s p e c i fi cd i a g n o s e sb y
PCPs. The obstacles to dementia diagnosis in primary care
a r ew e l ld o c u m e n t e da n di n c l u d ei m p o r t a n ts y s t e m si s s u e s
such as time constraints and lack of support services [12].
New models of dementia diagnosis and care are needed that
base resources in the primary care setting.
The lack of emphasis on a more accurate diagnosis of
dementia is linked to the absence of effective treatment
options. Active screening in older adults will be clearly justi-
fied once disease-modifying therapy is available. Specialized
neuroimaging and fluid biomarkers, now mostly used in
the research setting, are viable approaches to detecting early
and even preclinical AD [13, 14]. With emerging evidence of
geneticriskfactorsforsporadicAD,such asapolipoproteinE
(APOE) 𝜀4all e l e[ 15, 16], genotyping may also become incor-
p o r a t e di n t or o u t i n ea l g o r i t h m sf o rs c r e e n i n ga n dd i a g n o s i s .
Rates of ER visits and hospitalizations in the peri-
diagnostic period were substantial in all patients but notably
higher among patients seen by dementia specialists. One
explanation could be that dementia is often recognized in
the setting of acute cognitive or behavioral problems that
necessitate emergency care, prompting referral to specialists.
An important and unanswered question is whether earlier
diagnosis and management of cognitive impairment in the
primary care setting could help decrease morbidity and costs
associated with this increased resource utilization [17, 18].
Cholinesterase inhibitors and memantine are FDA
approved for the treatment of AD, for which they have
been shown to provide modest benefits. These drugs are
not approved for mild cognitive impairment or other types
of dementia, although they may have efficacy in dementia
with Lewy bodies [19]. In this study, about two-thirds of
patients with a final diagnosis of AD were prescribed a
dementia medication in the peri-diagnostic period, while
aboutone-thirdofpatientswithacodeforVDonlyorDNOS
also received dementia medication. VA formulary criteria
restrict the use of cholinesterase inhibitors to patients with
DAT, mixed DAT/vascular dementia, Lewy body dementia,
or dementia of PD, and memantine is approved for DAT
only [20]. However, dementia medications are widely used
off-label due the lack of therapies for other types of dementia
and the difficulty of excluding the presence of an Alzheimer’s
component of dementia [21].
4.1. Strengths and Weaknesses. Our study has a number of
strengths, including its large size and well-defined popula-
tion.Severallimitationsmustalsobeconsidered.TheVAHCS
is not a closed system, and it is impossible to accurately
identifypatientswho mayhaveoutsideproviders, complicat-
ing the interpretation of coding and resource utilization in
our dementia population. Diagnoses in this study are based
on ICD-9 coding and have not been validated by record
review; therefore, there may be misclassification of dementia.
Our study is limited to the New England region, and prior
research has shown that the prevalence of dementia varies by
VISN location [2]. Finally, our population is limited to the
veteran population, and generalizability to other populations
is uncertain.
5. Conclusion
This study presents an overview of current diagnostic and
treatment patterns for AD in a large veterans population.
Thedelaysinrecognitionofdementia,insufficientdiagnostic
assessment, and inappropriate use of dementia medication in
this study are not specific to the VA but remain important
targets for quality improvement. Additional medical record
review is needed in order to demonstrate the validity of
recorded dementia diagnoses, document the adequacy of
dementiaworkups,andestimatethelevelofcognitiveimpair-
ment of newly diagnosed patients with dementia. Finally,
a study of dementia using the national VA database would
generate important information about regional variations in
dementia care.
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